Morgan Stanley Maintains Equal-Weight on Pfizer, Lowers Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Pfizer (NYSE:PFE) and lowered the price target from $40 to $39.
October 17, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Pfizer and lowered the price target from $40 to $39.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Pfizer's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100